Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

About this update from Traws Pharma, Inc.

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio. The investigational combination utilizes a unique "dual-strike" mechanism of action that hijacks host cell pathways to force viral eradication. Importantly, both components of the combination have been safely evaluated in human studies as single agents. Viruses rely entirely on cellular infrastructure to replicate and are dependent on the host cell’s internal nucleotide pools. Traws Pharma’s novel combination therapy exploits this dependency through a coordinated, synergistic approach: Host Nucleotide Depletion: One component dynamically drains the host cell's natural nucleotide supply, creating a localized state of nucleotide starvation.Forced Lethal Incorporation: Deprived of natural substrates, the viral RNA-dependent RNA polymerase (RdRp) is forced to bind to and utilize the active nucleoside-mimics provided by the second component of our therapy. “By aggressively reducing the intracellular competition between natural nucleotides and the active drug, this mechanism drastically lowers the effective concentration (IC90) of the nucleoside prodrug required to completely halt replication. This maximizes the therapeutic potency against Hantavirus (Bunyavirus) Ebola (Filovirus) and Lassa (Arenavirus), while minimizing potential toxicity and achieving high efficacy at lower doses,” commented C. David Pauza, PhD, Chief Science Officer of Traws Pharma. The Company is advancing non-clinical development and evaluating the therapeutic combination in validated animal models of Hantavirus and Ebola. The criti...

View stock analysis, news, and events for Traws Pharma, Inc.